


# PRODUCT INFORMATION



## Daprodustat Item No. 19915

<b>CAS Registry No.:</b>	960539-70-2
<b>Formal Name:</b>	N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]-glycine
<b>Synonym:</b>	GSK1278863
<b>MF:</b>	C <sub>19</sub> H <sub>27</sub> N <sub>3</sub> O <sub>6</sub>
<b>FW:</b>	393.4
<b>Purity:</b>	≥98%
<b>UV/Vis.:</b>	λ <sub>max</sub> : 210, 265 nm
<b>Supplied as:</b>	A crystalline solid
<b>Storage:</b>	-20°C
<b>Stability:</b>	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



### Laboratory Procedures

Daprodustat is supplied as a crystalline solid. A stock solution may be made by dissolving the daprodustat in the solvent of choice. Daprodustat is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of daprodustat in ethanol is approximately 1 mg/ml and 3 mg/ml in DMSO and DMF.

Daprodustat is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, daprodustat should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Daprodustat has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Daprodustat is an inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that increases HIF stability and action. It is orally bioavailable, induces an effective erythropoietin (EPO) response, and stimulates non-EPO mechanisms of erythropoiesis in animal models. Daprodustat and related HIF prolyl hydroxylase inhibitors are in clinical trials for the treatment of anemia associated with chronic kidney disease.<sup>1,2</sup>

### References

1. Brigandi, R. A., Johnson, B., Oei, C., *et al.* A novel hypoxia-inducible factor—Prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial. *Am. J. Kidney Dis.* **67**(6), 861-871 (2016).
2. Schmid, H., Jelkmann, W. Investigational therapies for renal disease-induced anemia. *Expert Opin. Investig. Drugs* **25**(8), 901-16 (2016).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/19/2016

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)